IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 2.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 197,746 shares of the company's stock after purchasing an additional 4,230 shares during the period. IDEXX Laboratories makes up 1.3% of TimesSquare Capital Management LLC's holdings, making the stock its 19th largest position. TimesSquare Capital Management LLC owned approximately 0.24% of IDEXX Laboratories worth $83,043,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of IDXX. MorganRosel Wealth Management LLC purchased a new position in shares of IDEXX Laboratories in the first quarter valued at approximately $26,000. Hurley Capital LLC purchased a new position in IDEXX Laboratories during the fourth quarter worth about $29,000. Colonial Trust Co SC grew its stake in shares of IDEXX Laboratories by 84.8% in the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company's stock valued at $35,000 after buying an additional 39 shares in the last quarter. Itau Unibanco Holding S.A. lifted its position in shares of IDEXX Laboratories by 540.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock worth $40,000 after purchasing an additional 81 shares in the last quarter. Finally, Retirement Wealth Solutions LLC boosted its position in IDEXX Laboratories by 40.0% in the 1st quarter. Retirement Wealth Solutions LLC now owns 105 shares of the company's stock valued at $44,000 after buying an additional 30 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Down 1.4%

IDEXX Laboratories stock opened at $533.37 on Monday. The firm's 50 day moving average price is $519.68 and its two-hundred day moving average price is $459.58. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $549.52. The firm has a market cap of $42.89 billion, a PE ratio of 49.29, a P/E/G ratio of 3.89 and a beta of 1.54. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.81 and a current ratio of 1.16.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.93 by $0.03. The business had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. IDEXX Laboratories's quarterly revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.71 EPS. On average, research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on IDXX. Jefferies Financial Group began coverage on shares of IDEXX Laboratories in a research report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 price target for the company. Stifel Nicolaus raised their target price on shares of IDEXX Laboratories from $510.00 to $540.00 and gave the stock a "hold" rating in a research note on Wednesday, July 2nd. Wall Street Zen upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Saturday. Leerink Partners lifted their price target on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the company an "outperform" rating in a research report on Wednesday, June 11th. Finally, Morgan Stanley lifted their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research report on Monday, May 5th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $558.11.

Insider Activity

In other news, Director M Anne Szostak sold 1,260 shares of the stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the completion of the transaction, the director owned 1,801 shares in the company, valued at approximately $922,724.34. This represents a 41.16% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.98% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.